TWiV 1048: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses a molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, inhaled fluticasone furoate for outpatient treatment of COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, early antibody treatment, inflammation, and risk of post-COVID conditions, autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability, and multiorgan MRI findings after hospitalization with COVID-19 in the UK. Subscribe (free): Apple Podcasts , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode Molnupiravir -associated mutational signature in global SARS-CoV-2 genomes (Nature) Inhaled fluticasone furoate for outpatient treatment of COVID-19 (NEJM) Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID) Distinguishing features of Long COVID identified through immune profiling (Nature) Early antibody treatment , inflammation, and risk of post-COVID conditions (mBIO) Autonomic dysregulation in long-term patients suffering from post COVID-19 syndrome (SR) Multiorgan MRI findings after hospitalization with COVID-19 in the UK (The Lancet) Contribute to our Floating Doctors fundraiser at PWB Letters read on TWiV 1048 Dr. Griffin's COVID treatment summary ( pdf ) Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]